comparemela.com

Latest Breaking News On - First line treatment - Page 7 : comparemela.com

Johnson & Johnson : Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Lazertinib, in combination with RYBREVANT®▼ (amivantamab), for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer -December 21, 2023 at 08:44 am EST

News Release Media Contacts: Zayn Qureshi +44 7760 334666 Email: zqureshi@its.jnj.com Investor.

Region flamandeUnited statesCatherine taylorKiran patelZayn qureshiJanssen research developmentJanssen biotech incEuropean unionJanssen pharmaceutical companies of johnsonClinical developmentNational cancer instituteAmerican lung associationEuropean society of medical oncologyJanssen researchEuropean medicines agencyCilag gmbh international

MARIPOSA: Amivantamab, Lazertinib and Chemotherapy in Frontline EGFR-Mutant NSCLC

The panel reacts to the MARIPOSA trial, which looked at amivantamab, lazertinib, and chemotherapy in the front line in patients with EGFR-mutant non–small cell lung cancer.

Evolving treatment paradigmAdvanced nonSmall cell lung cancerNon small cell lung cancerAdvanced non small cell lung cancerAdvanced nsclcNsclc treatmentEgfr mutant lung cancerEgfr mutated lung cancerFirst line treatmentMariposa study

FLAURA2: Osimertinib and Chemotherapy in Frontline EGFR-Mutant NSCLC

Comprehensive insights on FLAURA2, which looked at osimertinib and chemotherapy in the front line for patients with EGFR-mutant NSCLC.

Evolving treatment paradigmAdvanced nonSmall cell lung cancerNon small cell lung cancerAdvanced non small cell lung cancerAdvanced nsclcNsclc treatmentEgfr mutant lung cancerEgfr mutated lung cancerFirst line treatmentBrain metastases

First-Line Treatment for EGFR-Mutant Advanced Lung Cancer

A panel of thoracic medical oncologists discuss the first-line treatment options for patients with EGFR-mutant advanced non–small cell lung cancer.

Evolving treatment paradigmAdvanced nonSmall cell lung cancerLine treatmentMutant advanced lungNon small cell lung cancerAdvanced non small cell lung cancerAdvanced nsclcNsclc treatmentEgfr mutant lung cancerEgfr mutated lung cancerFirst line treatmentBrain metastases

Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)

SOMERSET, N.J. (BUSINESS WIRE) Dec 11, 2023

United statesNew jerseyRoberto minaCiltacabtagene autoleucelYing huangJessie yeungAlexandra venturaAmerican cancer societyExchange commission onLegend biotech corporationAmerican society of hematology annual meetingClinical developmentEuropean organisation for researchJanssen biotech incDivision of hematologyUniversity of torino

vimarsana © 2020. All Rights Reserved.